Rodrigues Dominic 4
4 · PROVECTUS BIOPHARMACEUTICALS, INC. · Filed Jul 23, 2024
Insider Transaction Report
Form 4
Rodrigues Dominic
Director
Transactions
- Disposition to Issuer
Series D Convertible Preferred Stock
2024-06-25−11,416,242→ 0 totalFrom: 2022-09-16→ Common Stock (11,416,242 underlying) - Award
Series D-1 Convertible Preferred Stock
2024-06-25+1,141,626→ 1,141,626 totalFrom: 2024-06-25→ Common Stock (11,416,260 underlying)
Footnotes (5)
- [F1]Each share of Series D Convertible Preferred Stock, par value $0.001 per share ("Series D Convertible Preferred Stock") is convertible into one share of the Issuer's common stock, par value $0.001 per share ("Common Stock").
- [F2]On June 25, 2024, 11,416,242 shares of Series D Convertible Preferred Stock held by the Reporting Person were converted into 1,141,626 shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Convertible Preferred Stock"), pursuant to that certain Conversion Agreement, dated June 21, 2024, by and between the Reporting Person and the Issuer.
- [F3]The Series D Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D Convertible Preferred Stock.
- [F4]Each share of Series D-1 Convertible Preferred Stock is convertible into 10 shares of the Issuer's Common Stock.
- [F5]The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.